 |
|
Statin Use and Fracture Risk
Study of a US Veterans Population
Richard E. Scranton, MD, MPH;
Melissa Young, MPH;
Elizabeth Lawler, MPH;
Daniel Solomon, MD;
David Gagnon, MD, PhD;
J. Michael Gaziano, MD
Arch Intern Med. 2005;165:2007-2012.
Background Whether statins reduce the risk of fractures is still contested. Several studies support a favorable association, whereas post hoc analyses of statin-randomized trials have failed to find a benefit. We sought to assess this possible relationship in a large population of elderly, predominantly male veterans.
Methods We established the study population using all health care encounters and services from patients who received care in the New England Veterans Affairs health care system between January 1998 and June 2001. According to evidence from the literature, covariates that would affect the risk of fractures were included in the final model, as were medications that were clinically meaningful and significant in univariate models and the Charlson Comorbidity Index as a surrogate for general health. We also conducted a similar analysis among new statin users. We used pooled logistic regression to assess for significant associations.
Results Of the 91 052 patients in the final cohort, 28 063 were prescribed statins and 2195 were prescribed nonstatin lipid-lowering medications. In the adjusted analyses, statin use was associated with a 36% (odds ratio, 0.64; 95% confidence interval, 0.58-0.72) reduction in fracture risk when compared with no lipid-lowering therapy and a 32% (odds ratio, 0.67; 95% confidence interval, 0.50-0.91) reduction when compared with nonstatin lipid-lowering therapy. Similar findings were found for the new statin user group.
Conclusions We have provided yet another study in a unique population of mostly male veterans that found a significant reduction in fractures among statin users. More studies need to be performed to confirm or refute our findings.
Author Affiliations: Massachusetts Veterans Epidemiology Research Information Center (Drs Scranton, Gagnon, and Gaziano and Mss Young and Lawler), Divisions of Pharmacoepidemiology and Rheumatology (Dr Solomon) and Division of Aging (Drs Scranton and Gaziano), Brigham and Women’s Hospital, Harvard Medical School (Drs Scranton, Solomon, and Gaziano), and Department of Biostatistics, Boston University School of Public Health (Dr Gagnon), Boston.
RELATED LETTER
Statins and Fracture: Are All Variables Accounted For?
Jordan L. Geller and John S. Adams
Arch Intern Med. 2006;166(9):1041.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
The Association Between Statins and Cancer Incidence in a Veterans Population
Farwell et al.
JNCI J Natl Cancer Inst 2008;100:134-139.
ABSTRACT
| FULL TEXT
Effects of Atorvastatin on Bone in Postmenopausal Women with Dyslipidemia: A Double-Blind, Placebo-Controlled, Dose-Ranging Trial
Bone et al.
J. Clin. Endocrinol. Metab. 2007;92:4671-4677.
ABSTRACT
| FULL TEXT
Role of Human Valve Interstitial Cells in Valve Calcification and Their Response to Atorvastatin
Osman et al.
Circulation 2006;114:I-547-I-552.
ABSTRACT
| FULL TEXT
Statins and fracture: are all variables accounted for?
Geller and Adams
Arch Intern Med 2006;166:1041-1041.
FULL TEXT
|
